# K672977

# JUL 1 6 2008

# 510(k) Summary

This summary of $5 1 0 ( \mathbf k )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92

Submitter's name:

Diazyme Laboratories

Submitter's address:

12889 Gregg Court Poway, CA 92064 USA

# Name of Contact Person:

Dr. Abhijit Datta Diazyme Laboratories 12889 Gregg Court Poway, CA 92064 Phone: 858-455-4762 Fax: 858-455-2120

Date the Summary was Prepared:

September 24, 2007, June 5, 2008, and July 8, 2008

Name of the Device

Diazyme Apolipoprotein A-I Assay

Trade Name:

Diazyme Apolipoprotein A-I Assay

Common/Usual Name

Apolipoprotein A-I Test System

Device Classification Name

Lipoprotein test system

Product code:

MSJ (reagent), JT (calibrator), JJX (control)

Submission Type

510k

# Regulation Number

862.1475(reagent), 862.1150(calibrator), 862.1660(control)

Device Class

â…¡ (reagent),  (calibrator), I Reserved (control)

Predicate Device:

For the Alpha-1-lipoprotein Immunological Test System Lipoprotein test system, we are claiming equivalence [807.92(a) (3) to K-ASSAY APO AI ASSAY (k993345) manufactured by Kamiya Biomedical Company

# Substantial Equivalence Information

1. Predicate device name(s): K-Assay Apo AI Assay

2. Predicate 510(k) number(s): K993345

# 3. Comparison with predicate:

# Indications for Use

<table><tr><td>Diazyme Apolipoprotein A-I Assay</td><td>K-Assay Apo AI Assay</td><td>Equivalency</td></tr><tr><td>The Diazyme Apolipoprotein A-I Assay is For the quantitative determination of human intended for the in vitro quantitative Apolipoprotein Al (Apo AI) in serum by im- determination of apolipoprotein A-I (apo munoturbidimetric assay. A-I) in serum. It can be used as an aid forl assessing the risk of coronary artery disease.</td><td></td><td>Same</td></tr></table>

# Principle

<table><tr><td rowspan=1 colspan=1>Diazyme Apolipoprotein A-I Assay</td><td rowspan=1 colspan=1>K-Assay Apo AI Assay</td><td rowspan=1 colspan=1>Equivalency</td></tr><tr><td rowspan=1 colspan=1>This method is based on the reaction of a sam-ple containing human Apo A-I and specificantiserum to form an insoluble complex whichcan be measured turbidimetrically at 34Onm.By constructing a standard curve from the ab-sorbance of standards the concentration of ApoA-l can be determined.</td><td rowspan=1 colspan=1>This method quantifies Apolipoprotein AIbased on immunoturbidimetric assay. The re-agent uses a goat polyclonal antibody specificfor human Apolipoprotein Al. The antibodybinds to the Apo AI in the serum forminglight scattering immune complexes, whichincrease the turbidity of the sample. Since theturbidity is proportional to the amount of ApoAl in the sample, the Apolipoprotein Al con-centration can be determined by measuringthis increase in turbidity. The increase in tur-bidity is measured at 800 nm. ApolipoproteinAl in the sample is quantitatively determined.</td><td rowspan=1 colspan=1>Similar</td></tr></table>

# Test Objective

Type of Test   

<table><tr><td rowspan=1 colspan=1>Diazyme Apolipoprotein A-I Assay</td><td rowspan=1 colspan=1>K-Assay Apo AI Assay</td><td rowspan=1 colspan=1>Equivalency</td></tr><tr><td rowspan=1 colspan=1>The Diazyme LDL-Cholesterol Assay is in-tended for the in vitro quantitative determina-tion of Low Density Lipoprotein Cholesterolin human serum or plasma.</td><td rowspan=1 colspan=1>For the quantitative determination of humanApolipoprotein AI (Apo Al) in serum by im-munoturbidimetric assay.</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Diazyme Apolipoprotein A-I Assay</td><td rowspan=1 colspan=1>K-Assay Apo AI Assay</td><td rowspan=1 colspan=1>Equivalency</td></tr><tr><td rowspan=1 colspan=1>Quantitative</td><td rowspan=1 colspan=1>Quantitative</td><td rowspan=1 colspan=1>Same</td></tr></table>

# Specimen Type

<table><tr><td rowspan=1 colspan=1>Diazyme Apolipoprotein A-I Assay</td><td rowspan=1 colspan=1>K-Assay Apo AI Assay</td><td rowspan=1 colspan=1>Equivalency</td></tr><tr><td rowspan=1 colspan=1>Human serum</td><td rowspan=1 colspan=1>Human serum</td><td rowspan=1 colspan=1>Same</td></tr></table>

# Product Type

<table><tr><td rowspan=1 colspan=1>Diazyme Apolipoprotein A-I Assay</td><td rowspan=1 colspan=1>K-Assay Apo AI Assay</td><td rowspan=1 colspan=1>Equivalency</td></tr><tr><td rowspan=1 colspan=1>Calibrator, Reagent, Instrument</td><td rowspan=1 colspan=1>Calibrator, Reagent, Instrument</td><td rowspan=1 colspan=1>Same</td></tr></table>

# Performance

<table><tr><td>Diazyme Apolipoprotein A-I Assay</td><td>K-Assay Apo AI Assay</td></tr><tr><td>Reportable Range: Serum: 20- 228 mg/dL Precision/Serum: Within Run: 0.6% -0.9% Total: 1.8%3.3 % Accuracy/Serum: Correlation Coefficient: 0.9789 Slope/Intercept: y = 0.91+ 2.813</td><td>Reportable Range: Serum: 20 - 300 mg/dL Precision/Serum: Within Run: 1.51 % -1.87 % Total: 1.05 %-1.57 % Accuracy/Serum: Correlation Coefficient: 0.970 Slope/Intercept: y = 0.980x + 4.776 mg/dL</td></tr></table>

# Calibrator Comparison

<table><tr><td rowspan=1 colspan=1>Diazyme Apolipoprotein A-I Assay</td><td rowspan=1 colspan=1>K-Assay Apo AI Assay</td><td rowspan=1 colspan=1>Equivalency</td></tr><tr><td rowspan=1 colspan=1>Lyophilized form</td><td rowspan=1 colspan=1>Lyophilized form</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Diazyme Apolipoprotein A-I calibrator value istraceable to the WHO International ReferenceMaterial for Apo AI, Sp1-01.</td><td rowspan=1 colspan=1>K-Assay Apo AI calibrator value is traceableto the WHO International ReferenceMaterial for Apo AI, Sp1-01.</td><td rowspan=1 colspan=1>Same</td></tr></table>

# JUL 1 6 2008

General Atomics   
Diazyme Laboratories   
c/o Mr. Charles Yu, Quality System Manager   
12889 Gregg Court   
Poway, California 92064

Re: k072977 Trade Name: Diazyme Apolipoprotein A-I Assay; Diazyme Apolipoprotein A-I Calibrator, and Diazyme Apolipoprotein A-I Control, Regulation Number: 21 CFR 862.1475 Regulation Name: Lipoprotein test system Regulatory Class: Class I, meets the limitation to exemption in 862.9(c)(4) Product Code: MSJ, JIT, JJX Dated: June 5, 2008 Received: June 17, 2008

Dear Mr. Yu.

We have reviewed your Section 510(k) preinarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your devicc to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Jean M.Coopes, M.S. D.V.M. Jean M. Cooper, M.S., D.V.M.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indications for Use

510(k) Number: K072977

Device Name: Diazyme Apolipoprotein A-I Assay

Indications for Use: The Diazyme Apolipoprotein A-I Assay is intended for the in vitro quantitative determination of apolipoprotein A-I (apo A-I) in serum. It can be used as an aid for assessing the risk of coronary artery disease. For in vitro Diagnostic use.

# Calibrator:

For calibration of the Diazyme Apolipoprotein A-I Assay in serum. For in vitro Diagnosfic Use.

Controls:

To monitor the performance of Diazyme Apolipoprotein A-I Assay in serum.   
For in vitro Diagnostic Use.

![](images/5abe4898ef19b48c165380cea51d73e59fb4c15afa21df8a94644264af227568.jpg)

Office of in Virn Drgnostic Dovice Evaluation and Safcly 510(k) K072977